A new study published in PNAS Nexus suggests that painful neuromas are not simply bundles of misdirected nerve fibers. Instead, their axons appear to undergo a distinct molecular transformation that makes them unusually excitable and responsive to mechanical stimulation. Kyle Eberlin and colleagues examined the molecular architecture of ten painful neuromas removed during surgery and compared them with six healthy peripheral nerves obtained from lower-leg amputations performed for unrelated medical reasons. The comparison revealed a sharp shift in the identity and behavior of the nerve fibers inside the neuromas.

The researchers used immunofluorescent confocal microscopy, a technique that allows specific proteins and cellular structures to be labeled with fluorescent molecular markers and visualized in three dimensions. Neuroma and healthy-nerve samples were processed into sections 50 micrometers thick before staining. This approach enabled the team to map proteins associated with axonal regeneration, pain signaling, mechanical sensation, electrical excitability, and sympathetic innervation—the network of nerves involved in involuntary functions such as blood-vessel control.

Under the microscope, the axons within painful neuromas lacked the orderly organization seen in healthy nerves. Rather than running in aligned bundles toward a defined destination, the regenerating fibers formed irregular, densely packed structures. They also displayed high levels of markers associated with active growth and repair, indicating that the axons remained in a regenerative state even though they had failed to establish a functional connection with their target tissue.

One of the most striking findings involved calcitonin gene-related peptide, or CGRP. This neuropeptide is released by sensory neurons and plays a major role in transmitting and amplifying pain. CGRP can also contribute to inflammation and heightened sensitivity in injured tissues. In the neuroma samples, 84 percent of axons expressed CGRP, compared with only 3 percent of axons in healthy nerves. The difference suggests that a large proportion of the fibers in painful neuromas may be molecularly primed to detect and transmit nociceptive signals—the signals the nervous system interprets as potentially damaging or painful.

The neuromas also showed increased expression of Piezo2, a mechanically activated ion channel. Piezo2 opens when the cell membrane is deformed, allowing positively charged ions to enter the nerve cell and initiate electrical activity. In normal sensory neurons, this mechanism helps detect light touch, pressure, vibration, and body position. Within a disorganized neuroma, however, mechanical forces such as contact, stretching, or pressure may activate abnormal axonal endings. This could explain why even minor pressure against a scar or amputation site can trigger severe, shock-like pain.

Another important marker was Nav1.3, a voltage-gated sodium channel involved in the initiation and propagation of electrical impulses. Sodium channels are essential for nerve signaling, but their expression changes after injury. Elevated Nav1.3 can make damaged neurons more likely to fire spontaneously or respond excessively to weak stimuli. The researchers found that Nav1.3 was upregulated in the neuromas, adding another molecular indication that these nerve fibers had become hyperexcitable. Together, increased CGRP, Piezo2, and Nav1.3 point to a nerve structure simultaneously tuned for pain detection, mechanical sensitivity, and rapid electrical activation.

The study also identified an abundance of sympathetic nerve fibers within the painful neuromas. Sympathetic nerves are not traditionally considered the primary conductors of pain, yet growing evidence indicates that they can interact with injured sensory fibers and influence chronic pain. Chemical communication between sympathetic and sensory neurons may intensify inflammation or promote spontaneous activity in damaged axons. Their presence in the neuromas raises the possibility that the local nerve environment, rather than the sensory axons alone, contributes to persistent pain after nerve injury.

The findings may help explain why painful neuromas are difficult to treat and why conventional pain medicines do not always provide lasting relief. Current surgical approaches attempt to remove the abnormal tissue or redirect regenerating axons into muscle, bone, or other protective targets. The molecular profile described in this study suggests additional possibilities, including therapies designed to reduce CGRP signaling, inhibit abnormal Piezo2-mediated mechanosensation, or normalize Nav1.3 activity. Treatments that disrupt interactions between sympathetic and sensory fibers could represent another avenue. These possibilities remain experimental, and the study does not establish that any single marker causes neuroma pain.

The researchers emphasize that their work is based on a relatively small collection of human specimens, and the comparison between amputated nerves and surgically removed neuromas cannot capture every biological difference between patients. Nevertheless, studying human tissue directly provides a valuable view of the condition that animal models may not fully reproduce. Axonal regeneration is widespread across the animal kingdom, but the formation of painful neuromas appears to be a comparatively recent evolutionary development, emerging in birds and mammals. Understanding why regeneration becomes maladaptive in these species may ultimately reveal how healing turns into chronic pain—and how that process can be interrupted.

Subject of Research: Molecular characteristics and pain mechanisms of human painful neuromas.

Article Title: Painful neuromas exhibit axonal phenotypic shift via nociceptive and mechanosensitive marker up-regulation

News Publication Date: 11-Aug-2026

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/ffe0045b-cc00-42e9-ad96-94911df62e49/Rendition/low-res/Content/Public

References: PNAS Nexus, “Painful neuromas exhibit axonal phenotypic shift via nociceptive and mechanosensitive marker up-regulation.”

Image Credits: Aron Cserveny

Keywords: painful neuroma, peripheral nerve injury, chronic pain, axonal regeneration, CGRP, Piezo2, Nav1.3, mechanosensitivity, nociception, sympathetic nerve fibers, immunofluorescence, nerve amputation

Neuropathic pain, a chronic condition resulting from nerve injury or dysfunction, frequently co-occurs with anxiety and depression, creating a persistent cycle that severely diminishes quality of life. Despite clinical recognition, the precise molecular mechanisms bridging these conditions have remained elusive. The innovative methodologies employed in this study allow for an unprecedented dissection of the complex gene interactions that mediate this comorbid state, offering promising new avenues for targeted therapeutic interventions.

The researchers first applied WGCNA, a sophisticated bioinformatics tool that clusters genes into modules based on expression patterns across samples. This approach identifies groups of genes that work in concert rather than studying isolated candidates, reflecting more physiologically relevant insights. By applying WGCNA to transcriptomic data derived from neuropathic pain models exhibiting anxiodepression, the team mapped out discrete gene modules linked to both sensory and emotional disturbances. These susceptibility modules pinpoint genes that may coordinate responses to neuropathic insults and modulate mood-related neural circuits.

To complement the WGCNA findings, the study further utilized ceRNA network analysis, which delineates regulatory interactions between long non-coding RNAs, microRNAs, and messenger RNAs. This multi-layered RNA crosstalk has emerged as a pivotal gene regulation mechanism in various neurological diseases but remains underexplored in neuropathic pain-associated mood disorders. By constructing ceRNA networks, the investigators uncovered key hub genes and RNA molecules that serve as molecular sponges, modulating gene expression dynamics in neuropathic pain with secondary anxiodepression.

Among the discovered modules, several genes stood out due to their strong correlations with clinical phenotypes. These genes are involved in neuroinflammation, synaptic plasticity, and neurotransmitter signaling—all critical pathways implicated in chronic pain and mood dysregulation. Intriguingly, some candidate genes had not previously been connected to anxiodepression, underscoring the novelty of this systematic, network-based approach. Such findings highlight targets that may be ideal for future drug development or biomarker identification.

One of the remarkable aspects of this research lies in its integration of high-throughput sequencing data with cutting-edge computational biology, exemplifying the increasing importance of systems biology in unraveling brain disorders. By taking a holistic view of gene interactions rather than isolated effects, it transcends traditional paradigms and opens new frontiers for understanding neuropsychiatric complications arising from pain disorders.

Moreover, the study emphasizes the role of ceRNA networks as master regulators. These regulatory RNA molecules fine-tune gene expression post-transcriptionally, impacting how genes implicated in neural plasticity and immune response are expressed during neuropathic stress. This insight compels a paradigm shift where non-coding RNAs are no longer considered “junk” but essential elements orchestrating complex pathological states, offering rich targets for RNA-based therapeutics.

Beyond molecular neuroscience, the implications of this study reach into clinical and translational domains. Understanding the gene modules that predispose individuals to develop anxiodepression in the context of neuropathic pain paves the way for personalized medicine strategies. In the future, patients might be stratified based on their genetic risk profiles, tailoring interventions that modify maladaptive networks before full-blown psychiatric syndromes emerge, significantly improving prognosis and quality of life.

Furthermore, the identification of hub genes can accelerate biomarker discovery. Reliable biomarkers for neuropathic pain-induced anxiodepression remain scarce, hindering early diagnosis and treatment monitoring. The gene candidates from this research might serve as molecular signatures detectable in peripheral tissues, facilitating non-invasive diagnostics and real-time evaluation of therapeutic efficacy.

The study also ignites fresh debates regarding neuroimmune crosstalk in mood disorders. Many of the susceptibility modules are enriched for genes involved in inflammatory processes, echoing mounting evidence that neuroinflammation is a central player in both chronic pain and depression. This reinforces hypotheses that anti-inflammatory strategies could mitigate both physical and emotional suffering concomitantly, a promising avenue demanding further exploration.

From a technical perspective, this investigation showcases the strength of integrating WGCNA and ceRNA analyses, which complement each other by tackling gene co-expression and post-transcriptional regulation respectively. This dual approach serves as a blueprint for future research into complex disorders characterized by multifactorial gene regulation, offering a more comprehensive picture than traditional single-layer analyses.

The potential of translating these findings into clinical breakthroughs is immense but hinges on validating these gene networks in human tissues and diverse neuropathic pain conditions. The replication of results across cohorts and mechanistic studies dissecting how these gene interactions influence neuronal and glial function will be critical next steps. Nevertheless, the study’s methodology and insights represent a pivotal advance in neuropsychiatric genomics.

The repercussions of this research extend beyond neuropathic pain-induced anxiodepression. Similar network biology frameworks could unravel mechanisms underlying other co-morbid neuropsychiatric conditions, such as post-traumatic stress disorder or chronic fatigue syndrome, which also feature complex genetic and environmental interplay. This integrative systems approach may thus herald a new era of psychiatric genetics focused on network dynamics rather than isolated genetic loci.

Importantly, this study sheds light on the importance of considering brain disorders as systems affected by interconnected molecular cascades and RNA interactions. By moving away from the reductionist “one gene, one disease” model, it recognizes the biological complexity that governs brain function and malfunction, offering hope that revolutionary, network-targeted therapies might soon emerge to relieve millions affected by neuropathic pain and mood disorders worldwide.

In sum, the identification of susceptibility gene modules and their regulatory ceRNA networks in neuropathic pain-induced anxiodepression represents a seminal contribution to neuroscience. The breadth and depth of this study not only provide fresh mechanistic insights but also chart future courses for diagnostics, therapeutics, and holistic understanding of pain-related psychiatric comorbidity. Such visionary research undertakes the vital challenge of decoding the multilayered biological dialogues that shape human suffering and resilience.

As the scientific community digests these findings, the promise of translating systems biology into tangible clinical outcomes shines ever brighter. In bridging the gap between molecular complexity and patient-centered care, this landmark research marks a decisive step forward in our collective quest to unravel the enigmatic links between chronic pain and depression, offering hope for precision medicine interventions that could transform lives afflicted by this relentless dual burden.

Subject of Research: Genetic and molecular mechanisms underlying neuropathic pain-induced anxiodepression via WGCNA and ceRNA network analyses.

Article Title: Identification of susceptibility modules and genes through WGCNA and ceRNA network analysis in neuropathic pain-induced anxiodepression.

Article References:
He, Y., Xu, Y., Xing, F. et al. Identification of susceptibility modules and genes through WGCNA and ceRNA network analysis in neuropathic pain-induced anxiodepression. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04041-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04041-2